Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

Kirby Institute21 enrolled

Overview

This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within public hospital services.

This study will be conducted as a Phase IV, multicentre, sequential cohort trial. 60 participants will be enrolled from participating hospital inpatient services. They will be evaluated for eligibility by the use of rapid point-of-care (POC) confirmation of viraemia in people who inject drugs (PWID) hospitalised for IRID. The period of hospitalisation for management of IRID, particularly when prolonged, may represent an ideal opportunity to engage HCV-infected PWID and a potential important strategy for broader HCV elimination. Eligible patients will be enrolled into one of two treatment cohorts A and B. A) 30 patients will immediately commence treatment whilst an inpatient of G/P (glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis services post discharge (standard duration therapy). Following the successful completion of Cohort A, eligible patients will be enrolled into Cohort B. B) 30 patients will immediately commence treatment whilst an inpatient of 4 weeks of SOF/G/P (sofosbuvir/glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis services post discharge (short duration therapy). Any patient with recurrent viraemia during follow-up will be genotyped +/- sequenced to exclude re-infection. If relapse is confirmed the patient will be offered re-treatment with standard of care (SOC) salvage therapy based on results of resistance testing.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatitis C Liver Inflammation Liver Cirrhoses

Interventions

Glecaprevir/Pibrentasvir 100 MG-40 MG Oral TabletDRUG

8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily

Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral TabletDRUG

4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible to participate in this study. 1. Have voluntarily signed the informed consent form. 2. 18 years of age or older. 3. Injected drugs within the last 6 months 4. Hospitalised with an IRID with an anticipated inpatient stay of \> 1 week Participants must meet the following additional inclusion criteria to be treated in this study. 5. HCV RNA positive 6. Compensated liver disease 7. Documented non-cirrhotic at enrolment with a qualifying liver FibroScan ≤ 9.5 kpA 8. If co-infection with HIV is documented, the subject must meet the following criteria: 1. ART naïve with CD4 T cell count \>500 cells/mm3; OR 2. On a stable ART regimen (containing only permissible ART) for \>4 weeks prior to screening visit, with CD4 T cell count ≥200 cells/mm3 and a plasma HIV RNA level below the limit of detection. Exclusion Criteria: Participants who meet any of the exclusion criteria are not to be enrolled in this study. 1. Inability or unwillingness to provide informed consent or abide by the requirements of the study 2. Actively intoxicated. Participants that meet any of the additional exclusion criteria are not to be treated in this study. 3. History of any of the following: b. Clinical hepatic compensation (i.e. ascites, encephalopathy or variceal haemorrhage) c. Solid organ transplant d. History of severe, life-threatening or other significant sensitivity to study drugs (glecaprevir/pibrentasvir/sofosbuvir) or any excipients of the study drugs 4. Creatinine clearance (CLcr) \< 30 mL/min at screening (Cohort B only) 5. Pregnant or nursing female 6. Decompensated liver disease 7. Use of prohibited concomitant medications 8. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent \> 10 mg/day for \>2 weeks) 9. Prior treatment failure with an NS5A based DAA regimen Patients without an IRID but who fulfill all other criteria and are admitted with an expected duration of stay \> 1 week may also be included at discretion of study team.

Locations (7)

Prince of Wales Hospital

Randwick, New South Wales, Australia

St Vincent's Hospital Sydney

Sydney, New South Wales, Australia

Blacktown Mt Druitt Hospital

Sydney, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia

Outcomes

Primary Outcomes

SVR12 outcomes for all total patient population

To evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID and commencing inpatient DAA treatment within public hospital services.

Time frame: 12 weeks post completion of commenced treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.